article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

America’s profit-riddled healthcare-industrial complex consumes 17% of GDP, equivalent to $3.6trn a year. However, changes are slowly being implemented that could lower healthcare costs. Healthcare is ripe for disruption, but any attempt to disrupt our state of healthcare has been met with pushback and challenges.

article thumbnail

Europe publishes first list of critical medicines

European Pharmaceutical Review

The European Commission, the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the first Union list of critical medicines. The list contains more than 200 active substances that are considered “critical for healthcare systems” across the EU/EEA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Is digital the future of medicine?

World of DTC Marketing

Some 70% of American hospitals still fax and post patient records, and patients don’t have one record to share among all their doctors. Digital medicine has been thrust into the spotlight because of the pandemic and the media hype is in overdrive. ” Digital medicine also needs better clarification.

Medicine 201
article thumbnail

NICE recommends first medicine for severe alopecia areata

European Pharmaceutical Review

The National Institute for Health and Care Excellence (NICE) has recommended LITFULO ® (ritlecitinib) for treating certain patients with severe alopecia areata. However, on 31 October 2023, a marketing authorisation in Great Britain was granted for the medicine ritlecitinib. “It Ritlecitinib is subject to additional monitoring.

article thumbnail

Value-based healthcare can help reduce costs

World of DTC Marketing

Why haven’t more employers addressed the rising costs of employee healthcare with value-based care? This has to be upsetting to employers experiencing riding employee healthcare costs. The answer may be in offering a value-based healthcare model. Value-based models encourage a team-oriented approach to patient care.

article thumbnail

MHRA approves ‘safer’ medicine alternative for rare disease

European Pharmaceutical Review

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree ® (vamorolone), as a safer alternative to corticosteroids, for Duchenne muscular dystrophy (DMD). “In The medicine is indicated in patients who are four years of age and over, independent of the underlying mutation and ambulatory status.

article thumbnail

Vertex scores European cystic fibrosis medicine approval

European Pharmaceutical Review

The biotech added that for UK patients, following approval by the Medicines and Healthcare products Regulatory Agency (MHRA) on 15 November 2023, and an existing reimbursement agreement between Vertex and the NHS, children two years and older can access this expanded KAFTRIO (ivacaftor/tezacaftor/elexacaftor) indication.